(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.98%) $81.13
(-2.36%) $1.944
(-0.20%) $2 298.40
(-0.30%) $26.58
(-0.33%) $945.10
(0.09%) $0.938
(0.24%) $11.12
(0.06%) $0.801
(0.00%) $93.45
Live Chart Being Loaded With Signals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...
Stats | |
---|---|
आज की मात्रा | 1 479.00 |
औसत मात्रा | 1 477.00 |
बाजार मूल्य | 1.79M |
EPS | $0 ( 2023-09-29 ) |
Last Dividend | $0.150 ( 2024-01-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.12 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Common Stock |
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Warrants (right to buy) |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Common Stock |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Warrants (right to buy) |
2023-06-30 | Rombotis Spiro George | Buy | 110 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 4 220 559 | Sell: 12 |
Cyclacel Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
ALSA | 0.919 |
LCAA | 0.913 |
XFIN | 0.908 |
ALXN | 0.905 |
IQ | 0.905 |
PLYA | 0.904 |
JUGG | 0.902 |
IVCP | 0.901 |
VPCB | 0.901 |
TIOAU | 0.9 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
SIDU | -0.91 |
MTP | -0.902 |
JAGX | -0.902 |
EVLO | -0.892 |
ENNV | -0.89 |
PROC | -0.889 |
DBGI | -0.885 |
LGMK | -0.885 |
TRMK | -0.883 |
SLNG | -0.879 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Cyclacel Pharmaceuticals वित्तीय
Annual | 2023 |
राजस्व: | $420 000 |
सकल लाभ: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2023 |
राजस्व: | $420 000 |
सकल लाभ: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2022 |
राजस्व: | $0 |
सकल लाभ: | $-32 000.00 (0.00 %) |
EPS: | $-32.23 |
FY | 2021 |
राजस्व: | $0.00 |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-9.93 |
Financial Reports:
No articles found.
Cyclacel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.150 | 2006-01-18 |
Last Dividend | $0.150 | 2024-01-19 |
Next Dividend | $0 | N/A |
Payout Date | 2024-02-01 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $8.85 | -- |
Avg. Dividend % Per Year | 5.36% | -- |
Score | 4.44 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 0.683 | -- |
Year | Amount | Yield |
---|---|---|
2006 | $0.600 | 14.50% |
2007 | $0.600 | 11.20% |
2008 | $0.600 | 12.60% |
2009 | $0.150 | 7.89% |
2010 | $0 | 0.00% |
2011 | $0.300 | 7.71% |
2012 | $0 | 0.00% |
2013 | $0.600 | 6.67% |
2014 | $0.750 | 8.13% |
2015 | $0.450 | 6.96% |
2016 | $0.600 | 15.30% |
2017 | $0.600 | 9.68% |
2018 | $0.600 | 9.16% |
2019 | $0.600 | 9.60% |
2020 | $0.450 | 9.00% |
2021 | $0.600 | 8.53% |
2022 | $0.600 | 9.68% |
2023 | $0.600 | 5.19% |
2024 | $0.150 | 0.91% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -53.86 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -2.57 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.00889 | -1.000 | -0.0889 | 0.0889 | [0 - 1] |
currentRatioTTM | 0.912 | 0.800 | -0.439 | -0.351 | [1 - 3] |
quickRatioTTM | 0.773 | 0.800 | -0.157 | -0.126 | [0.8 - 2.5] |
cashRatioTTM | 0.414 | 1.500 | 8.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 239.38 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -9.44 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0610 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0580 | 1.000 | -2.37 | -2.37 | [0.2 - 0.8] |
operatingProfitMarginTTM | -61.55 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -435.46 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0477 | 0.800 | -3.02 | -2.41 | [0.5 - 2] |
Total Score | -3.63 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0513 | 1.000 | -0.106 | 0 | [1 - 100] |
returnOnEquityTTM | -3.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.00889 | 1.500 | -0.0889 | 0.0889 | [0 - 1] |
pegRatioTTM | -0.00147 | 1.500 | -3.34 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -38.36 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.53 |
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं